

Special Issue

World Lung Cancer Awareness Month

Message from the Guest Editor

Lung cancer is the most common malignancy in many parts of the world. It is often diagnosed late and has one of the poorest outcomes amongst other cancers. The landscape and management of lung cancer in general has also changed dramatically in the last decade, perhaps more than any other thoracic disease. Advances in surgery and cancer genetics facilitate personalized drug therapies that can provide ever more complex and innovative treatment algorithms to fight this terrible disease. The role of liquid biopsies, more targeted bespoke drug therapies, non-invasive endoscopic treatments, and high-precision surgeries are only some of the evolving horizons in lung cancer management.

November 2022 is designated as "World Lung Cancer Awareness Month". We would like to take this opportunity to appreciate all the researchers who have contributed to the fight against this disease. In particular, we would like to highlight several researches in this field, which cover mechanisms in the tumor microenvironment, early detection, promising therapeutic targets, and new therapeutic strategies. We hope this Special Issue will provide useful information for clinical practice.

Guest Editor

Prof. Dr. Calvin Sze Hang Ng
Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China

Deadline for manuscript submissions

closed (15 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/148426

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)